Super Antioxidant 120 caps

Συνδυασμός αντιοξειδωτικών ουσιών, με αντιφλεγμονώδεις δράσεις , δράσεις ενάντια στην υπέρταση και στα υψηλά επίπεδα της LDL χοληστερόλης.

Το άλφα λιποϊκό οξύ είναι ενδογενής συμπαράγοντας που βρίσκεται σε όλα τα ευκαρυωτικά κύτταρα και συμμετέχει στην παραγωγή ενέργειας

Σε κλινικές δοκιμές το άλφα λιποϊκό οξύ έδειξε ότι ήταν σημαντικός παράγοντας στη μείωση της αντίστασης στην ινσουλίνη και στην χαλάρωση των αγγείων.

Η ρεσβερατρόλη είναι μια πολυφαινόλη που βρίσκεται σε μικρές δόσεις στην φλούδα και στα κουκούτσια του κόκκινου σταφυλιού και έχει σημαντική αντιοξειδωτική δράση και ιδιότητες.

Η κουρκουμίνη παράγεται από το σχετικό φυτό που φύεται στην νότια Ασία.

Το πράσινο τσάι είναι πλούσιο σε φυσικά φλαβονοϊδή. Η συχνή χρήση πράσινου τσαγιού μειώνει το αίσθημα της κόπωσης.

Η κερσετίνη είναι φλαβονοεϊδές το οποίο βρίσκεται στα μήλα, στα διάφορά είδη τσαγιού, στα κόκκινα μούρα, στα κεράσια, στα κίτρα και ιδίως στο κρεμμύδι. Χρησιμοποιείται κυρίως ως ισχυρό αντιοξειδωτικό. Δεν συντίθεται από τον ανθρώπινο οργανισμό και πρέπει να λαμβάνεται με την διατροφή.

Η επίδραση της C έχει μελετηθεί εκτενώς και ενδέχεται να βοηθά στην μείωση της κούρασης και της κόπωσης.

Συμπλήρωμα διατροφής

Περιεχόμενο: 120 κάψουλες

Ενεργά συστατικά Ημερήσια δόση (1 κάψουλα) %Σ.Η.Π.*
Α-λιποϊκό οξύ 62,5 mg **
Ρεσβερατρόλη 6,25 mg **
Εκχύλισμα ρίζας τουρμερικού 125 mg **
Εκχύλισμα φύλλων πράσινου τσαγιού 40% EGCG 125 mg **
Βιταμίνη C (ως L-ασκορβικό οξύ) 75 mg 93,75 %
Κερκετίνη 125 mg **

*Συνιστώμενη Ημερήσια Ποσότητα (ΣΗΠ) **Δεν έχει θεσπισθεί ΣΗΠ

Συστατικά: Μικροκρυσταλλική κυτταρίνη, στεατικό μαγνήσιο, διοξείδιο του πυριτίου.

To προϊόν παράγεται στην Ευρωπαϊκή Ένωση σύμφωνα με τους Κανόνες Καλής Παρασκευής (GMP).


Λαμβάνετε 1 κάψουλα ημερησίως ή σύμφωνα με τις οδηγίες του γιατρού σας. Να μην υπερβαίνετε την συνιστώμενη ημερήσια δόση.

Οδηγίες για τη φύλαξη του προϊόντος: Το προϊόν διατηρείται σε δροσερό και ξηρό μέρος. Φυλάσσεται μακριά από μικρά παιδιά.

Τα συμπληρώματα διατροφής δεν πρέπει να χρησιμοποιούνται ως υποκατάστατο μιας ισορροπημένης δίαιτας. Συμβουλευτείτε τον γιατρό σας πριν καταναλώσετε το προϊόν εάν είσθε έγκυος ή θηλάζετε.

86492/11-11-2013

Ο Αριθμός Γνωστοποίησης δεν επέχει θέση άδειας κυκλοφορίας από τον ΕΟΦ

1. Van de MK, Chen JS, Steliou K, Perrine SP, Faller DV. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol 2003;194:325-40.

2. Simbula G, Columbano A, Ledda-Columbano GM, et al. Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis 2007 Jan;12(1):113-23.

3. Shi DY, Liu HL, Stern JS, et al. Alpha-lipoic acid induces apoptosis in hepatoma cells via the PTEN/Akt pathway. FEBS Lett. 2008 May 28;582(12):1667-71.

4. Jacob S, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309-14.

5. Gu XM, Zhang SS, Wu JC, et al. Efficacy and safety of high-dose á-lipoic acid in the treatment of diabetic polyneuropathy. Zhonghua Yi Xue Za Zhi. 2010 Sep;90(35):2473-2476.

6. Heinisch BB, Francesconi M, Mittermayer F, et al. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest. 2010 Feb;40(2):148-54.

7. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet.Med 2004;21:114-21.

8. Ziegler D, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999 Aug;22(8):1296-301.

9. Ruhnau k, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec;16(12):1040-3.

10. Marshall AW, et al. Treatment of alcohol-related liver disease with thioctic acid: a six month randomized double-blind trial. Gut 1982;23:1088-93.

11. Park KG, Min AK, Koh EH, et al. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate- activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 2008 Nov;48(5):1477-86.

12. Beitner H. Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% alpha-lipoic acid related to photoageing of facial skin. Br J Dermatol 2003;149:841-9.

13. Hall SS. Longevity research. In vino vitalis? Compounds activate life-extending genes. Science. Aug 29 2003;301(5637):1165.

14. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. Sep 11 2003;425(6954):191-196.

15. Fauconneau B, Waffo-Teguo P, Huguet F, et al. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 1997;61(21):2103-2110.

16. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. Mar 31 1995;235(2):207-219.

17. Tome-Carneiro J, Gonzalvez M, Larrosa M, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. The American journal of cardiology. Aug 1 2012;110(3):356-363.

18. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacological research : the official journal of the Italian Pharmacological Society. Jun 2012;65(6):615-620.

19. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. The American journal of clinical nutrition. Jun 2010;91(6):1590-1597.

20. Wong RH, Howe PR, Buckley JD, et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutrition, metabolism, and cardiovascular diseases: NMCD. Nov 2011;21(11):851-856.

21. Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clinical hemorheology and microcirculation. 2012;50(3):179-187.

22. Brasnyo P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. The British journal of nutrition. Aug 2011;106(3):383-389.

23. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. The journals of gerontology Series A, Biological sciences and medical sciences. Dec 2012;67(12):1307-1312.

24. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism. Nov 2 2011;14(5):612-622.

25. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes. Nov 28 2012.

26. Chen Y, Tseng SH, Lai HS, et al. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery. Jul 2004;136(1):57-66.

27. ElAttar TM, Virji AS. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs. Feb 1999;10(2):187-193.

28. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. Jun 1999;179(3):297-304.

29. Surh YJ, Hurh YJ, Kang JY, et al. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett. Jun 1 1999;140(1-2):1-10.

30. Gehm BD, McAndrews JM, Chien PY, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A. Dec 9 1997;94(25):14138-14143.

31. Wang TT, Hudson TS, Wang TC, et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis. Oct 2008;29(10):2001-2010.

32. Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovascular research. Jun 1 2011;90(3):538-545.

33. Bachmeier BE, Mirisola V, Romeo F, et al. Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin. Cell Physiol Biochem. 2010;26(3):471-482.

34. Cemil B, Topuz K, Demircan MN, et al. Curcumin improves early functional results after experimental spinal cord injury. Acta Neurochir (Wien). Sep 2010;152(9):1583-1590; discussion 1590.

35. Seehofer D, Schirmeier A, Bengmark S, et al. Inhibitory effect of curcumin on early liver regeneration following partial hepatectomy in rats. J Surg Res. Aug 2009;155(2):195-200.

36. Yun JM, Jialal I, Devaraj S. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem. May 2011;22(5):450-458.

37. Jantan I, Bukhari SN, Lajis NH, et al. Effects of diarylpentanoid analogues of curcumin on chemiluminescence and chemotactic activities of phagocytes. J Pharm Pharmacol. Mar 2012;64(3):404-412.

38. Chang KW, Hung PS, Lin IY, et al. Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression. Int J Cancer. Jul 1 2010;127(1):9-20.

39. Siwak DR, Shishodia S, Aggarwal BB, et al. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer. Aug 15 2005;104(4):879-890.

40. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene. Oct 27 2005;24(47):7022-7030.

41. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. Apr 15 2007;67(8):3853-3861.

42. Selvendiran K, Ahmed S, Dayton A, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther. Nov 1 2011;12(9):837-845.

43. Sreekanth CN, Bava SV, Sreekumar E, et al. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. Jul 14 2011;30(28):3139-3152.

44. Qiao Q, Jiang Y, Li G. Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-kappaB pathway: an in-vitro study of lymphoma. Anticancer Drugs. Jan 23 2012.

45. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. Apr 1 2008;14(7):2128-2136.

46. Ng TP, Chiam PC, Lee T, et al. Curry consumption and cognitive function in the elderly. Am J Epidemiol. Nov 1 2006;164(9):898-906.

47. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. Feb 2008;28(1):110-113.

48. Bundy R, Walker AF, Middleton RW, et al. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. Dec 2004;10(6):1015-1018.

49. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterol Hepatol. Dec 2006;4(12):1502-1506.

50. Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, et al. Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med. Aug 2009;15(8):891-897.

51. Pungcharoenkul K, Thongnopnua P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res. Nov 2011;25(11):1721-1726.

52. Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. Dec 2007;56(6):509-514.

53. He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. Mar 2011;29(3):208-213.

54. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. Jul 15 2008;14(14):4491-4499.

55. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. Jan 2010;9(1):8-14.

56. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. Jul 2011;68(1):157-164.

57. Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010;62(8):1137-1141.

58. Morsy MA, Abdalla AM, Mahmoud AM, et al. Protective effects of curcumin, alpha-lipoic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats. J Physiol Biochem. Oct 11 2011.

59. Bulku E, Stohs SJ, Cicero L, et al. Curcumin exposure modulates multiple pro-apoptotic and anti-apoptotic signaling pathways to antagonize acetaminophen-induced toxicity. Curr Neurovasc Res. Feb 1 2012;9(1):58-71.

60. Hsu SD, et al. Chemoprevention of oral cancer by green tea. Gen Dent 2002;50:140-6.

61. Pisters KM, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19:1830-8.

62. Proniuk S, et al. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention. J Pharm Sci 2002;91:111-6.

63. Sartippour MR, et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 2002;132:2307-11.

64. Sun CL, et al. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis 2002;23:1497-503.

65. Nechuta S, Shu XO, Li HL, et al. Prospective cohort study of tea consumption and risk of digestive system cancers: results from the Shanghai Women's Health Study. Am J Clin Nutr. 2012 Nov;96(5):1056-63. doi: 10.3945/ajcn.111.031419. Epub 2012 Oct 10.

66. Lee YK, et al. VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic Lymphocytic Leukemia. Blood 2004;104(3):788-94.

67. Maron DJ, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med. 2003 Jun 23;163(12):1448-53.

68. Yang YC, et al.The protective effect of habitual tea consumption on hypertension. Arch Intern Med. 2004 Jul 26;164(14):1534-40.

69. Brown AL, Lane J, Coverly J, et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr. Aug 19 2008:1-9.

70. Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans.BMC Pharmacol. Aug 26 2004;4:18.

71. Venables MC, Hulston CJ, Cox HR, Jeukendrup AE. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr. Mar 2008;87(3):778-784.

72. Mackenzie T, Leary L, Brooks WB. The effect of an extract of green and black tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. Metabolism. Oct 2007;56(10):1340-1344.

73. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006;296(10):1255-65.

74. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.J Eur Acad Dermatol Venereol. Nov 2007;21(10):1404-1412.

75. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.Br J Dermatol. Jun 2008;158(6):1329-1338.

76. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. Jun 2008;111(6):1371-1379.

77. Lamson DW, Brignall MS. Antioxidant and cancer III: quercetin. Altern Med Rev 2000;5:196-208.

78. Graefe EU, et al. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Therapy 1999;37:219-33.

79. Erlund I, et al. Pharmacokinetics of quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000;56:545-53.

80. Sampson S, et al. Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 2002;102:1414-20.

81. Akan Z, Garip AI. Antioxidants May Protect Cancer Cells from Apoptosis Signals and Enhance Cell Viability. Asian Pac J Cancer Prev. 2013;14(8):4611-4614.

82. Shoskes D, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999;54:960-3.

83. Janssen K, et al. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and dietary supplement study. Am J Clin Nutr 1998;67:255-62.

84. Chopra M, et al. Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin Chem 2000;46:1162-70.

85. Beatty ER, et al. Effect of dietary quercetin on oxidative DNA damage in healthy human subjects. Br J Nutr 2000;84:919-25.

86. Ferry DR, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996;2:659-68.

87. Sergent T, Dupont I, Van der Heiden E, et al. CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol Lett. 2009 Dec 15;191(2-3):216-22.

88. Singh B, Mense SM, Bhat NK, et al. Dietary quercetin exacerbates the development of estrogen-induced breast tumors in female ACI rats. Toxicol Appl Pharmacol. 2010 Sep 1;247(2):83-90.

89. Askari G, Ghiasvand R, Feizi A, Ghanadian SM, Karimian J. The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J Res Med Sci. 2012 Jul;17(7):637-41.

90. Chen YW, Chou HC, Lin ST, et al. Cardioprotective Effects of Quercetin in Cardiomyocyte under Ischemia/Reperfusion Injury. Evid Based Complement Alternat Med. 2013;2013:364519.

91. Sharmila G, Bhat FA, Arunkumar R, et al. Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clin Nutr. 2013 Sep 3. [Epub ahead of print]

92. Wang G, Zhang J, Liu L, Sharma S, Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One. 2012;7(12):e51764.

93. Rinwa P, Kumar A. Quercetin suppresses the microglial neuroinflammatory response and induces anti-depressant like effect in olfactory bulbectomized rats. Neuroscience. 2013 Oct 1. [Epub ahead of print]

94. Meng B, Gao W, Wei J, et al. Quercetin reduces serum homocysteine level in rats fed a methionine-enriched diet. Nutrition. 2013 Apr;29(4):661-6.

95. Afkhami-Ardekani M, Shojaoddiny-Ardekani A. Effect of vitamin C on blood glucose, serum lipids & serum insulin in type 2 diabetes patients. Indian J Med Res. Nov 2007;126(5):471-474.

96. Ochoa-Brust GJ, Fernandez AR, Villanueva-Ruiz GJ, et al. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007;86(7):783-787.

97. Nathens AB, Neff MJ, Jurkovich GJ, et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Annals of surgery. Dec 2002;236(6):814-822.

98. Foley DJ, White LR. Dietary intake of antioxidants and risk of Alzheimer disease: food for thought. JAMA : the journal of the American Medical Association. Jun 26 2002;287(24):3261-3263.

99. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA : the journal of the American Medical Association. Jun 26 2002;287(24):3223-3229.

100. Zojaji H, Talaie R, Mirsattari D, et al. The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Sep 2009;41(9):644-647.

101. Mathew MC, Ervin AM, Tao J, et al. Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract. The Cochrane database of systematic reviews. 2012;6:CD004567.

102. Chong EW, Wong TY, Kreis AJ, et al. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. Bmj. Oct 13 2007;335(7623):755.

103. Gomez-Cabrera MC, Domenech E, Romagnoli M, et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. The American journal of clinical nutrition. Jan 2008;87(1):142-149.

104. Muralikrishnan G, Amanullah S, Basha MI, et al. Effect of vitamin C on lipidperoxidation and antioxidant status in tamoxifen-treated breast cancer patients. Chemotherapy. 2010;56(4):298-302.